SBIA
MDGL icon

Sheaff Brock Investment Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.16M Hold
3,500
– – 0.11% 162
2024
Q4 		$1.08M Hold
3,500
– – 0.09% 164
2024
Q3 		$743K Hold
3,500
– – 0.07% 204
2024
Q2 		$981K Sell
3,500
-100
-3% -$23.8K 0.09% 169
2024
Q1 		$961K Buy
+3,600
New +$848K 0.06% 191
2016
Q1 		– Sell
-9,143
Closed -$113K – 667
2015
Q4 		$113K Buy
+9,143
New +$251K 0.01% 572

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sheaff Brock Investment Advisors's MDGL Position: Q1 2025 in Review

Sheaff Brock Investment Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2025 at 3,500 shares worth $1.16M. The position accounts for 0.11% of the portfolio, ranked #162.

Sheaff Brock Investment Advisors first reported a position in MDGL in Q4 2015 and has held it in 6 quarters since. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

  • Sheaff Brock Investment Advisors held 3,500 shares of Madrigal Pharmaceuticals worth $1.16M as of Q1 2025.
  • Sheaff Brock Investment Advisors left its Madrigal Pharmaceuticals share count unchanged in Q1 2025.
  • Madrigal Pharmaceuticals made up 0.11% of Sheaff Brock Investment Advisors's portfolio in Q1 2025, its #162 holding.
  • Sheaff Brock Investment Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2015 and has held it in 6 quarters since.
  • 321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2025, filed 7 May 2025.